Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07079657 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Thulium Laser and Growth Factors for Androgenetic Alopecia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 23, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
Trial Details
NCT Number NCT07079657
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Conditions
(from sponsor)
Androgenetic Alopecia (AGA)
Related terms Alopecia
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov